TED THOMPSON

Advocating for a ban on Trichloroethylene (TCE) and paraquat. H.R.9233 - The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act of 2024 - a bill to create a Centers of Excellence grant program within the National Institute of Health to focus on the intersection between environmental risk factors and neurodegenerative disease. Efforts to ban paraquat.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons. Efforts to ban paraquat.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons. Efforts to ban paraquat.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons. Efforts to ban paraquat.

General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals. H.R.9233/S. - The HEALTHY BRAINS Act: Draft legislation to create a Centers of Excellence grant program within the National Institutes of Health to focus on the intersection between environmental risk factors and neurodegenerative diseases. Supporting FDA Neurology Drug Program Funding: Advocacy for funding through the FY 2025 Agriculture Appropriations bills (H.R. 9027, S. 4690) and the Labor, Health and Human Services FY 2025 Appropriations bill (not yet filed). S.269 - Protect America's Children from Toxic Pesticides Act (PACTPA): Legislation focused on protecting children from harmful pesticides, including those linked to Parkinson's. S.806 - The Healthy H2O Act: A bill that addresses concerns about water quality and its effects on health, relevant to Parkinsons disease prevention. Neurodegenerative Disease Center of Excellence: Ongoing development of a legislative proposal to create a center at the National Institute of Environmental Health Sciences (NIEHS) to focus on neurodegenerative diseases like Parkinsons.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS).

General education regarding environmental triggers of neurological disease and Parkinson's along with support for more research. S.269, the Protect America's Children from Toxic Pesticides Act (PACTPA). More protective standards for particulate matter pollution. More protective standards for pesticides. Opposition to H.R.277 REINS Act of 2023.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS).

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S. 269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

General education regarding environmental triggers of neurological disease and Parkinson's along with support for more research. S.269, the Protect America's Children from Toxic Pesticides Act (PACTPA). More protective standards for particulate matter pollution. More protective standards for pesticides. Opposition to H.R.277 REINS Act of 2023.

General education regarding environmental triggers of neurological disease and Parkinson's along with support for more research. S.269, the Protect America's Children from Toxic Pesticides Act (PACTPA). More protective standards for particulate matter pollution.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

Lobbying to increase prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. S. 3109- Alleviating Barriers for Caregivers (ABC) Act- bill to require the Administrator of the Centers for Medicare & Medicaid Services and the Commissioner of Social Security to review and simplify the processes, procedures, forms, and communications for family caregivers to assist individuals in establishing eligibility for, enrolling in, and maintaining and utilizing coverage and benefits under the Medicare, Medicaid, CHIP, and Social Security programs respectively, and for other purposes.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS).

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. H.R.4752/S.2379 - the Concentrating High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2023: a bill to better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimers and related dementias, including Parkinson's disease dementia, in their earliest stages. Signed Leaders Engaged on Alzheimer's Disease (LEAD) Coalition letter to members of Congress in support of this legislation. H.R.4942/S.655 - the Conrad State 30 and Physician Access Reauthorization Act: a bill to reauthorize the Conrad State 30 program for three years, make several targeted policy improvements, and permit the gradual expansion of the number of waivers granted to each state to address health care provider shortages. Signed American Academy of Neurology letter to member of Congress in support of this legislation. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Patient and Provider Advocates for Telehealth coalition comment letter in response to CMS CY 2024 Medicare Physician Fee Schedule (PFS) in support prioritizing the needs of patients by expanding policies that improved access to safe and timely health care via telehealth. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

FY 2022 Appropriation bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration FY 2023 Appropriations bills including Parkinson's research funding requests for: Department of Defense National Institute of Health Centers for Disease Control and Prevention Food and Drug Administration Department of Veterans Affairs H.R.2617 Consolidated Appropriations Act, 2023 H.R.5376 Inflation Reduction Act of 2022

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act

General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"